Research ArticleA phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
Keywords: AUC; area under the plasma concentration-time curve; BMI; body mass index; EC50; 50% effective inhibitory concentration; EC90; 90% effective inhibitory concentration; HCV; hepatitis C virus; PEG-IFN; peginterferon alfa; RBV; ribavirin; NS5A protein; Vir